ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference ITF Therapeutics LLC shares significant data on givinostat for Duchenne muscular dystrophy at the 2026 MDA Clinical Conference. Learn about their presentations.

ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference #USA #Orlando #ITF_Therapeutics #DUVYZAT #givinostat

🔗Lee el artículo completo en el siguiente link: theakarifoundation-pr.org/blog

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #ITFTherapeutics #Givinostat #DUVYZAT #somoselcorazóndeladistrofia #AkariAgosto

ITF Therapeutics nos comparte nuevos datos importantes sobre la seguridad y eficacia a largo plazo de DUVYZAT, los cuales se publicaron la semana pasada en la revista Annals of Clinical and Translational Neurology.

#TheAkariFoundation #DistrofiaMuscularDeDuchenne #ITFTherapeutics #DUVYZAT

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy Positive long-term safety and efficacy data for Duvyzat (Givinostat) as a treatment for Duchenne muscular dystrophy (DMD) were published today by ITF Therapeutics, an Italfarmaco affiliate. The data came from the company's open-label extensions of its Phase 2 and Phase 3 (EPIDYS) trials. 🎈 New data published in Annals of Clinical and Translational Neurology show that long-term treatment with givinostat can significantly delay loss of key mobility functions in patients with Duchenne muscular dystrophy. 🎈 Meaningful clinical benefit was observed across treatment groups, regardless of disease stage at initiation. 🎈 Givinostat remained well-tolerated during extended use, consistent with previous clinical trials. 🎈 Average follow-up in the extension study exceeded 36 treatment months, with some patients receiving treatment for over eight years since initiating givinostat treatment. #givinostat #duvyzat 👉 Read More: DMDWarrioR.com

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

#givinostat #duvyzat

👉 Read More: DMDWarrioR.com

ITF Therapeutics Unveils Key Patient-Reported Data for DUVYZAT® in Duchenne Muscular Dystrophy at ISPOR 2025 ITF Therapeutics presents significant patient-reported outcome data for DUVYZAT® (givinostat) in Duchenne muscular dystrophy at ISPOR 2025, enhancing quality of life insights.

ITF Therapeutics Unveils Key Patient-Reported Data for DUVYZAT® in Duchenne Muscular Dystrophy at ISPOR 2025 #USA #DUVYZAT #Concord #Duchenne_Muscular_Dystrophy #Italfarmaco

Italfarmaco closes on EU okay for Duchenne drug Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

NEWS: #Italfarmaco's oral HDAC inhibitor #Duvyzat has been recommended for approval in the EU as a treatment for #Duchennemusculardystrophy, setting it on course to become the first non-steroidal option for patients with all #geneticvariants of the disorder.

pharmaphorum.com/news/italfar...

EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Duvyzat (givinostat) as a treatment for Duchenne muscular dystrophy (DMD) in patients from the age of six who are able to walk. The European Medicines Agency (EMA) has suggested that Duvyzat (givinostat) be given a conditional marketing authorization in the EU to treat Duchenne muscular dystrophy (DMD) in individuals who can walk starting at age six. Duvyzat is a suspension that is given orally in conjunction with corticosteroid therapy.

EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy

#dmd #duchenne #ema #duvyzat #givinostat

👉 DMDWarrioR.com

Long-Term Efficacy and Safety Data of DUVYZAT™ Presented at MDA Conference ITF Therapeutics LLC shares important long-term data on DUVYZAT™ (givinostat) for Duchenne muscular dystrophy, highlighting safety and effectiveness at MDA conference.

Long-Term Efficacy and Safety Data of DUVYZAT™ Presented at MDA Conference #USA #Dallas #DUVYZAT #Duchenne #givinostat

ITF Therapeutics Opens New Headquarters in Concord to Enhance Rare Disease Solutions ITF Therapeutics has opened a new headquarters in Concord, Massachusetts, focusing on rare diseases and community engagement. Aimed at fostering collaboration, it will serve as a hub for patient advocacy.

ITF Therapeutics Opens New Headquarters in Concord to Enhance Rare Disease Solutions #USA #ITF_Therapeutics #DUVYZAT #Concord #Italfarmaco

ITF Therapeutics to Present Groundbreaking Findings at MDA 2025 Conference in Dallas ITF Therapeutics LLC announces acceptance of seven abstracts for poster presentations at the 2025 MDA Conference showcasing DUVYZAT’s impact on DMD patients.

ITF Therapeutics to Present Groundbreaking Findings at MDA 2025 Conference in Dallas #USA #Dallas #ITF_Therapeutics #DUVYZAT #Duchenne

Like they paid our cost! So we would hit our max out of pocket. So the rest of the year insurance covers everything.

And we owe nothing.

This is the best present right now. I have no words. Just a lot of tears. The manufacturer of this drug is #ITF_therapeutics & the drug is #givinostat #duvyzat

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD)

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #givinostat #duvyzat #mhra #uk #england

ITF Therapeutics Welcomes Erica L. Monaco as New COO to Lead Operational Efforts ITF Therapeutics LLC has appointed Erica L. Monaco as its new Chief Operating Officer, bringing a wealth of experience in the pharmaceutical and financial industries.

ITF Therapeutics Welcomes Erica L. Monaco as New COO to Lead Operational Efforts #USA #ITF_Therapeutics #Erica_Monaco #DUVYZAT #Concord